Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura

Francesco Zaja, Marta Lisa Battista, Maria Teresa Pirrotta, Salvatore Palmieri, Michela Montagna, Nicola Vianelli, Luciana Marin, Margherita Cavallin, Monica Bocchia, Marzia Defina, Micaela Ippoliti, Felicetto Ferrara, Francesca Patriarca, Maria Antonietta Avanzini, Mario Regazzi, Michele Baccarani, Miriam Isola, Franca Soldano, Renato Fanin

Research output: Contribution to journalArticlepeer-review


Rituximab 375 mg/m2 weekly for four weeks has significant activity in patients with immune thrombocytopenia. We evaluated the activity of lower dose rituximab (100 mg iv weekly for 4 weeks) in 28 adults with idiopathic thrombocytopenic purpura. Overall (platelet count > 50×10 9/L) and complete responses (platelet count > 100×10 9/L) were achieved in 21/28 (75%) and 12/28 (43%) patients respectively. The median time to response and time to complete response were 31 and 44 days respectively. After a median follow-up of 11 months (range 3-18), 7/21 (33%) patients relapsed and 3 needed further treatments. In patients with idiopathic thrombocytopenic purpura, lower dose rituximab seems to show similar activity to standard dose.

Original languageEnglish
Pages (from-to)930-933
Number of pages4
Issue number6
Publication statusPublished - Jun 2008


  • B-cell depletion
  • Immune thrombocytopenia
  • Lower dose rituximab

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura'. Together they form a unique fingerprint.

Cite this